Loading...
Start 2017-10-23T10:46:19+00:00

Biovica is uniquely positioned to address one of the major challenges in cancer therapy today; how to better evaluate therapeutic efficacy and improve quality of life in patients with advanced stages of the disease.

A simple blood sample

DiviTum™ is an innovative biomarker assay developed with the aim to monitor and predict treatment response in cancer therapy. It offers several advantages over alternative techniques that are standard in advanced breast cancer. In several clinical trials, the DiviTum™ biomarker assay has demonstrated the potential to quickly evaluate treatment effect and accurately predict outcome using just a simple blood sample.

Read more about DiviTum

New unique data from US breast cancer congress

The results demonstrate that palbociclib significantly reduced serum TK-activity levels in patients with hormone sensitive, HER2- breast cancer already after 2 weeks of treatment. DiviTum™ measured changes in serum TK-activity that was significantly correlated to the tumor Ki67 proliferation index. DiviTum™ may thus serve as a non-invasive marker and early response indicator of the anti-tumor effect of CDK4/6 inhibitors like palbociclib.

Read more about the study

About Biovica

Biovica, a Swedish biotech company founded in 2009, develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and better predict patient outcome. Biovica is supported by The European Commission and has been selected to receive funding in the Horizon 2020 phase 2 program.

Read more about Biovica

New Operations Manager at Biovica

Uppsala, December 5, 2017. Biovica has appointed Adam Germunder as new Operations Manager. Adams responsibilities include to build and secure the company’s production capabilities and ensure that they meet regulatory requirements in preparation for the commercialization of DiviTum®.

Read More

Researchers at Washington University report: DiviTum® can evaluate the biologic activity of blockbuster breast cancer drug after two weeks

Uppsala, Sweden, November 23, 2017. Results of a study from Washington University, St Louis, demonstrate that the DiviTum® can evaluate the biologic activity of Pfizer’s breast cancer drug palbociclib (Ibrance®) in just two weeks are published in the latest edition of the scientific journal Breast Cancer Research and Treatment. This shortening of the response evaluation window can improve outcome and increase quality of life for breast cancer patients.

Read More

New study results support use of DiviTum® for evaluation of pancreatic cancer

Uppsala, Sweden, November 21, 2017. In collaboration with University of Heidelberg, Germany, results from a clinical study of pancreatic cancer is published in the Pancreas scientific journal. The results demonstrate that Biovica’s DiviTum assay can provide an accurate prognosis and evaluation of treatment efficacy.

Read More

‘Best-possible-treatment’

from day one

Breast cancer

Breast cancer is the most common form of cancer among women today, affecting approximately 362,000 individuals in the EU and 233,000 in the US each year. Better tests for evaluating therapeutic efficacy, such as Biovica’s DiviTum™ biomarker assay, aim to increase survival and improve quality of life.

Read more about market need

Clinical trials and Collaborations

Biovica has successfully worked to realize its vision for Divitum™ by initiating collaborations with globally-renowned research institutes such as the Karolinska Institute and the Dana Farber Cancer institute, as well as the International Breast Cancer Study Group (IBCSG) and the Breast International Group (BIG).

Read more about clinical trials